Eli Lilly has lowered the price of its weight-loss drug Zepbound for patients paying out of pocket and introduced two new available vial doses.

Eli Lilly is offering higher-dose vials through its direct-to-consumer website, LillyDirect, which started offering lower doses in vials in August.

Last week, Eli Lilly said it would cut the monthly price ... WATCH: Lawmakers challenge drug company CEO over steep prices ...

Eli Lilly partnered up with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial ...

Eli Lilly has launched new 7.5 mg and 10 mg single-dose vials of Zepbound (tirzepatide), priced at $499 per month under the ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro ... David Ricks, Eli Lilly’s chief executive officer, told CNN that the company – whose revenue grew 32% to $45 ...

Eli Lilly announced in a press release last week that it has reduced the prices of vials of its popular anti-obesity drug Zepbound and introduced new dosage options. The company is now offering 7. ...

Zepbound ® and its delivery device base are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates. LillyDirect ® is a registered trademark owned or ...

The partnership comes as telehealth companies grapple with restrictions on the sale of some compounded GLP-1s.

Eli Lilly is expanding the supply and cutting the costs of its weight-loss drug Zepbound, broadening access to more patients without insurance. The company launched 7.5 mg and 10 mg vials of ...

Eli Lilly is now offering four doses of Zepbound in self-administration vials. The lower-cost self-pay option targets people ...